

Pr **JAMP**
Prasugrel

≤75 years | No prior history
≥60 kg | of stroke/TIA




JOIN HERE FOR
MORE TOOLS >



- Convenient once daily dosing¹
- Superior efficacy to Ticagrelor in the most recent head-to-head comparison²
- Fewer risk of drug interactions (NSAID, Clarithromycine, azole antifungals)¹
- Alternative therapy if rash or dyspnea with other P2Y12 inhibitors¹



www.jamppharma.ca | 1310, rue Nobel, Boucherville QC J4B 5H3
Tél. : 450 449-1236 | Sans frais : 1 866 399-9091



**NOW
AVAILABLE**
for you and
your patients



Reimbursed in your province
and by private insurers



Less expensive than Ticagrelor
\$1.67 vs **\$2.96** (daily cost)³

**CANADIAN
COMPANY** 

Pr **JAMP**
Prasugrel

≤75 years | No prior history
≥60 kg | of stroke/TIA



JAMP Prasugrel, co-administered with acetylsalicylic acid (ASA), is indicated for the early and long-term secondary prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) as follows⁴:

- ST-segment elevation myocardial infarction (STEMI) managed with primary or delayed percutaneous coronary intervention (PCI).
- Unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI) managed with PCI.

Consult the Product Monograph for contraindications, warnings and precautions, clinical use, adverse reactions, interactions, dosing, and administration.

Consult the Product Monograph by clicking [HERE](#).

References:

1. Lordkipanidzé M *et al.*, Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada, CJC Open (2021), doi: <https://doi.org/10.1016/j.cjco.2020.11.021> 2. ISAR-REACT 5: Schüpke S *et al.* Ticagrelor or Prasugrel in patients with acute coronary syndromes. *New Engl J Med.* 2019. (epub doi 10. 1056/NEJMoa 1908973):1-11 3. Régie de l'assurance maladie. Liste des médicaments, 14 avril 2021. <https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste-med-2021-04-14-fr.pdf>. Consulté le 17 mai 2021. 4. JAMP Prasugrel Product Monograph. JAMP Pharma Corporation, July 16,2020.



www.jamppharma.ca | 1310, rue Nobel, Boucherville QC J4B 5H3
Tél. : 450 449-1236 | Sans frais : 1 866 399-9091

ABOUT JAMP PHARMA GROUP



Canadian pharmaceutical
company founded in 1988



Continually developing new products:
35 new products approved last year;
nearly **80 other products to come**



More than 20 molecules used
in cardiology



A reliable supply chain
thanks to high inventory levels

If you have questions or for patients
of Health Canada's special access
programs, please contact
serviceclient@jamppharma.com

